ImmunoCellular Therapeutics, Ltd. reported unaudited consolidated earnings results for the first quarter ended March 31, 2017. For the quarter, the company reported revenue was $4,658,720 compared with $4,737,575 a year ago. Loss before other income was $5,478,898 compared with $5,837,407 a year ago. net loss was $5,824,987 compared with $5,633,345 a year ago. Basic and diluted net loss per share was $1.64 compared with $2.47 a year ago. Cash used in operations in the first quarter of 2017 was $6.1 million compared to $5.4 million in the prior year quarter.